What Can You Expect in 2026?
The 2nd TRP Target Selection & Drug Design Summit is the only meeting dedicated to reimagining how the next generation of radiopharmaceuticals is discovered, designed, and translated into the clinic.
Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval and others will address the fundamental questions shaping the field:
- How do we expand beyond PSMA and SSTR2 without compromising specificity?
- What is the optimal isotope for a given biological mechanism?
- How can kidney and salivary toxicity be meaningfully reduced?
- What design strategies maximize tumor retention?
- Where can RLT best synergize with DDR agents and immunotherapies?
- How can preclinical dosimetry more reliably predict clinical outcomes?
If your work focuses on smarter vector design, improving isotope and target selection, advancing alpha and beta emitters, or creating cleaner translational paths, this is where those critical conversations happen. Join 100+ radiochemists, drug developers, and R&D decision-makers working to move the field beyond incremental advances - and toward more precise, more potent, and longer-lasting therapies for patients.
Unmissable Event Highlights
Perfect your isotope match and harness alpha, beta, and Auger emitters for greater tumor killing power with less kidney and salivary toxicity
Supercharge RLT combinations with DDR inhibitors, checkpoint blockade, and CAR-T to break resistance and boost efficacy at lower doses
Design smarter vectors using pretargeting, biparatopic antibodies, and intracellular trapping to maximize tumor retention and minimize off-target exposure
Fast-track translation with imaging-guided dosimetry, PK insights, and novel linker - chelator chemistry for rapid, confident Phase 0/FIH decisions
Move beyond “me-too” targets and advance Trop-2, DLL3, and B7-H3 for better patient stratification and longer-lasting clinical responses
Explore the Full Event Guide
- 100+ Attendees
- 20+ Expert Speakers
- 12+ C-Suite Speakers
- 6+ Hours of Built-In Networking
- 3 Big Pharma Companies
Attending Companies Include
Explore the Agenda
Discover how the field’s leaders are redefining target selection, isotope pairing, and translational strategy to unlock the next era of radioligand therapy.
Partner With Us
Connect with RLT decision-makers searching for partners in targeting, imaging, radiochemistry, and isotopes to drive faster, safer radiopharmaceutical development.
Join RLT Experts
Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.